KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual ObligationsCost Of SalesEmployee StatisticsGross Margin %Gross Margin Annual %Gross ProfitGross Profit AnnualIncome Before Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Expense SegregationOpex As A % Of RevenueProperty, Plant & Equipment, Net BreakdownR&D As A %R&D SegregationRevenueRevenue By Customer TypeRevenue By Customer Type %Revenue By ProductRevenue By Product %Revenue By Product AnnualRevenue By Product Annual %Revenue By SegmentRevenue By Segment %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Gross Profit: 2009-2025

Historic Gross Profit for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $257.0 million.

  • Acadia Pharmaceuticals' Gross Profit rose 10.99% to $257.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $962.5 million, marking a year-over-year increase of 13.07%. This contributed to the annual value of $876.0 million for FY2024, which is 27.91% up from last year.
  • Acadia Pharmaceuticals' Gross Profit amounted to $257.0 million in Q3 2025, which was up 5.39% from $243.8 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Gross Profit peaked at $257.0 million during Q3 2025, and registered a low of $104.4 million during Q1 2021.
  • For the 3-year period, Acadia Pharmaceuticals' Gross Profit averaged around $207.8 million, with its median value being $223.7 million (2024).
  • Data for Acadia Pharmaceuticals' Gross Profit shows a peak YoY skyrocketed of 58.98% (in 2023) over the last 5 years.
  • Over the past 5 years, Acadia Pharmaceuticals' Gross Profit (Quarterly) stood at $120.0 million in 2021, then grew by 11.72% to $134.1 million in 2022, then skyrocketed by 58.98% to $213.2 million in 2023, then increased by 11.56% to $237.8 million in 2024, then grew by 10.99% to $257.0 million in 2025.
  • Its last three reported values are $257.0 million in Q3 2025, $243.8 million for Q2 2025, and $223.9 million during Q1 2025.